Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.54 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.51 |
| ▸ | FABP4 | P15090 | 4/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.48 |
| ▸ | PYGL | P06737 | 5/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841537 | 0.81 | CXCR5 (0.71) | CXCR2CXCR5PYGLERAP1CYP2C9 | |
| SCHEMBL485588 | 0.78 | CXCR2 (0.64) | CXCR2CXCR5PYGLERAP1CYP2C9 | |
| SCHEMBL485768 | 0.78 | CXCR2 (0.52) | CXCR2CXCR5PYGLERAP1CYP2C9 | |
| SCHEMBL485769 | 0.74 | CXCR2 (0.68) | CXCR2CXCR5PYGLCYP2C9 | |
| SCHEMBL485565 | 0.74 | ERAP1 (0.50) | CXCR2CXCR5FABP4FABP5PYGL | |
| SCHEMBL3926632 | 0.73 | CXCR2 (0.86) | CXCR2CXCR5PYGLCYP2C9 | |
| SCHEMBL3936452 | 0.72 | CXCR2 (0.75) | CXCR2CXCR5PYGLCYP2C9 | |
| SCHEMBL2240626 | 0.72 | WDR5 (0.81) | CYP2C9WDR5 | |
| SCHEMBL9856947 | 0.72 | WDR5 (0.63) | WDR5 | |
| SCHEMBL485654 | 0.72 | CXCR2 (0.59) | CXCR2CXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-7919628-B2 | 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184177-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885CXCR5 5/4885FABP4 1785/4885 |
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885CXCR5 5/4885FABP4 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.